Financial Performance - Total Revenues for Q2 2025 reached $825 million, a 16% year-over-year increase[17, 22] - VOXZOGO revenue in Q2 2025 was $221 million, representing a 20% year-over-year growth[17, 22] - Enzyme Therapies revenue in Q2 2025 was $555 million, a 15% year-over-year increase[17, 22] - Non-GAAP Operating Margin for Q2 2025 was 39.9%, an increase of 8.7 percentage points year-over-year[25] - Non-GAAP Diluted EPS for Q2 2025 was $1.44, a 50% increase year-over-year[17, 30] - Operating Cash Flow for Q2 2025 was $185 million, a 55% increase year-over-year[30] - The company increased FY'25 Total Revenues guidance to $3,125 million to $3,200 million[24, 34] - The company increased FY'25 Non-GAAP Diluted EPS guidance to $4.40 to $4.55[33, 34] Product and Pipeline Updates - VOXZOGO's contribution to full-year 2025 Total Revenues is expected to be in the range of $900 million to $935 million[24, 34] - BMN 333 Phase 1 data showed >3x AUC PK free CNP levels vs other long-acting CNP[17, 45] - Submissions for PALYNZIQ age eligibility expansion for adolescents (12-17 y/o) in the U S and Europe are planned for 2H 2025[3, 48, 51, 56]

Financial Performance - Revuforj net revenue in 2Q25 reached $28.6 million, representing a 43% quarter-over-quarter growth[6] - Niktimvo net revenue reported by Incyte in 2Q25 was $36.2 million, a substantial increase from $13.6 million in the first two months of Q1 launch[9] - Syndax reported $9.4 million in collaboration revenue from Niktimvo in 2Q25, achieving profitability in the first full quarter[9] - Syndax holds a strong financial position with $518 million in cash and equivalents as of June 30, 2025[28] Product Pipeline and Market Opportunity - Syndax estimates a $5B+ Total Addressable Market (TAM) for Revuforj and another $5B+ TAM for Niktimvo, indicating a $10B+ market opportunity across R/R and frontline indications[4, 30] - The initial Niktimvo indication represents a $2B U S market opportunity, with potential for label and geographic expansion leading to a $5B+ TAM[19, 20] - Approximately 33% of KMT2A patients are estimated to have proceeded to hematopoietic stem cell transplantation (HSCT) following Revuforj treatment[6, 12] Clinical Data and Development - Phase 2 Relapsed/Refractory (R/R) mNPM1 AML data for Revumenib showed a 26% (20/77) CR+CRh rate and a 48% (37/77) Overall Response Rate (ORR)[26] - Phase 1 R/R NUP98r AML data for Revumenib showed a 60% (3/5) ORR[26] - Over 80% of bone marrow transplant centers have ordered Niktimvo[18]

Financial Performance - SI-BONE achieved 21.7% worldwide revenue growth, reaching $48.6 million in the second quarter of 2025[8] - U S revenue grew by 22.8% to $46.4 million in the second quarter of 2025[8] - The company reported a gross margin of 79.8%, an improvement of 80 basis points[8] - Adjusted EBITDA was positive at $1.0 million, marking the third consecutive quarter of positive AEBITDA[8, 16] - The company generated $1.1 million in net cash[8] - SI-BONE has $145.5 million in cash and equivalents[17] Market and Physician Engagement - U S active physicians increased by 25%[8, 10] - The company has experienced 18 consecutive quarters of double-digit U S active physician growth[13] Guidance and Future Opportunity - SI-BONE updated its 2025 worldwide revenue guidance to $195 - $198 million, implying a growth of approximately 17%-18% year-over-year[21] - The company estimates a total U S addressable market opportunity of over $3.5 billion[23, 31] - iFuse TORQ TNT received NTAP with payment of $4,136[8, 59]

Financial Performance - Denny's system-wide same-restaurant sales increased by 3.7% YTD in 2025[4] - Keke's Q2 2025 LTM system AUV sales reached $1.9 million[4] - Denny's Q2 2025 domestic average weekly sales were approximately $38,400[14] - Denny's allocated over $713 million towards share repurchases since the program began in late 2010[49] - Denny's has approximately $88 million remaining under existing repurchase authorization[49] Sales Mix and Trends - Denny's off-premises sales mix was 16% YTD in 2025[4] - Keke's off-premises sales were approximately 16% during Q2 2025[12] - Over 65% of Denny's overall domestic Q2 2025 sales were during the breakfast and lunch dayparts[16] Restaurant Footprint and Franchise - Denny's has a total of 1,484 restaurants[4] - Denny's has 1,321 restaurants in the U S[23] - Denny's international presence includes 163 restaurants in 14 countries and U S Territories[23] - Keke's operates 74 cafes in seven different states[43]

Financial Performance - Net sales reached $1.388 billion, a 32% increase year-over-year and a 25% sequential increase[12, 14] - Adjusted EBITDA was $338 million, a 79% year-over-year increase and a 41% sequential increase[12, 14] - RemainCo (ANS and Ruckus) net sales were $513 million, a 58% increase year-over-year and a 32% sequential increase[12, 14] - RemainCo Adjusted EBITDA was $127 million, a 326% increase year-over-year and a 101% sequential increase[9, 12] - The company is revising its 2025 Adjusted EBITDA guideposts up to between $1.15 billion and $1.20 billion, with RemainCo expected to contribute between $325 million and $350 million[11] Strategic Initiatives - The company entered into a definitive agreement to sell its CCS business to Amphenol for $10.5 billion in cash, expected to close in the first half of 2026[9] - The company anticipates approximately $500 million in fees and taxes related to the CCS sale[9] - The company intends to use the proceeds from the CCS sale to pay off debt and preferred equity and distribute excess cash, with minimal leverage on RemainCo[9] Liquidity and Debt - The company ended the quarter with over $991 million in available liquidity, including $571 million in cash[26] - Net leverage as of June 30, 2025, was 6.6x based on pro forma Adjusted EBITDA from continuing operations of approximately $1.025 billion[24, 25] Segment Performance - Connectivity and Cable Solutions (CCS) net sales increased by 20% year-over-year, driven by Cloud and Hyperscale datacenter growth, with EBITDA margin remaining strong at 24.1%[16] - Access Network Solutions (ANS) net sales increased by 65% year-over-year, with Adjusted EBITDA increasing by 132% due to DOCSIS 4.0 product revenue and increased license sales[16] - Ruckus net sales increased by 47% year-over-year, driven by a return to stabilized buying patterns in the channel, with Adjusted EBITDA increasing by $51 million[16]

Bitcoin Treasury Strategy - Semler Scientific aims to amplify stockholder returns through a Bitcoin treasury strategy focused on equity exposure to BTC using intelligent leverage[10] - The company strategically issues debt and equity securities, and utilizes potential operating cash flow to acquire BTC[10] - As of July 31, 2025, Semler Scientific held 5,021 BTC with a total market value of $586.2 million and an unrealized fair value gain of $110.4 million[12, 13] - Semler Scientific targets accumulating 105,000 Bitcoin by FY 2027E[21, 23] - The company plans to use operating cash flow (~$72 million, 15%), convertible bonds (~$89 million, 19%), and ATM issuances (~$315 million, 66%) to fund Bitcoin purchases[25] Financial Performance (Q2 2025) - Semler Scientific reported revenues of $8.2 million in Q2 2025, a 43.2% year-over-year increase[70] - The company recognized an unrealized gain of $83.8 million in Q2 2025 from the change in fair value of its Bitcoin holdings[70] - Net income for Q2 2025 was $66.9 million, or $5.71 per basic share and $5.04 per fully diluted share[70] - As of June 30, 2025, Semler Scientific's cash, cash equivalents, and restricted cash balance was $13.6 million[70] Capital Markets Activities - Semler Scientific issued 4.1 million shares of common stock through ATM in Q2 2025 for net proceeds of $156.6 million[77] - Post-quarter end through July 31, 2025, the company issued 1.1 million shares of common stock through ATM for net proceeds of $47.8 million[77]

Financial Performance & Growth - Q2 2025 total test reports for core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased by 33% year-over-year compared to Q2 2024[14, 61] - Gross Margin for Q2 2025 was 77%, while Adjusted Gross Margin reached 80%, slightly lower than the 81% and 83% respectively in the same period of 2024[14] - Net cash provided by operations in Q2 2025 was $20.8 million, a decrease from $24.0 million in Q2 2024[14] - As of June 30, 2025, the company's cash, cash equivalents, and marketable investment securities totaled $275.9 million[14] - Net income for Q2 2025 was $4.5 million, and Adjusted EBITDA was $10.4 million[14] Strategic Initiatives - The company aims to achieve operating cash flow positivity by the end of 2025[4, 60] - The company closed its acquisition of Previse, a gastrointestinal health company, focusing on chronic acid reflux related diseases, including esophageal cancer[14] - The company entered into a collaboration and license agreement with SciBase to develop diagnostic tests for dermatologic diseases[14] Market Penetration & Clinical Utility - DecisionDx-Melanoma clinical use is associated with improved patient survival, with a 29% lower 3-year melanoma-specific mortality and a 17% lower 3-year overall mortality in tested patients compared to untested patients[38] - DecisionDx-SCC Class results predict an SCC patient's individual metastatic risk and individual benefit of ART[44] - TissueCypher is the strongest independent predictor of progression to HGD or EAC in Barrett's esophagus patients, detecting 62% of progressors[51, 52]

Financial Performance - Q2 2025 revenue reached $78 million, showing a year-over-year growth of 16%[8] - Q2 2025 gross profit was $62 million, resulting in a gross profit margin of 79%[8] - Q2 2025 Adjusted EBITDA was $3 million, representing 4% of revenue[8] - The company had $56 million in cash and $20 million in debt at the end of Q2 2025[8] User Engagement - ThredUp had 1.5 million active buyers in Q2 2025, a 17% increase year-over-year[8] - Total orders in Q2 2025 amounted to 1.5 million, reflecting a 21% year-over-year growth[8] Sustainability Impact - ThredUp's operations have saved 666 million pounds of carbon emissions[8] - The company has also contributed to saving 1.3 billion kWh of energy[8] - Water savings attributed to ThredUp's efforts amount to 7 billion gallons[8] Market Position and Strategy - The U S secondhand apparel market grew 14% in 2024, which is 5 times faster than the broader retail clothing market[38] - The U S throws away approximately 17 billion pounds of apparel that could be recycled and reused[39]

Financial Performance - Net investment income increased to $2.5 million, or $0.83 per share, driven by incentive fee reversal[9] - Total expenses were a benefit of $864,000, reflecting a $1.5 million capital gains incentive fee reversal[9] - Total investment income decreased by 25% due to repayments exceeding originations[9, 32] - Adjusted expenses decreased 38% to $626,000 in Q2 2025, excluding the capital gains incentive fee benefit[32] - Net Asset Value (NAV) decreased from $65.3 million to $56.7 million[35] Portfolio Composition and Activity - The fair value of the investment in Tilson Technologies decreased by $9.5 million due to bankruptcy filing[20] - Portfolio mix at quarter-end: 86% fixed-rate debt investments and 14% equity investments in private companies[17] - Annualized weighted average yield of debt investments was 12.2% at June 30, 2025[17] - Total investments at fair value of $52.4 million[24] Liquidity and Dividends - Ended the quarter with approximately $25 million in liquidity and no debt[9] - Maintained quarterly dividend at $0.29 per share[38] - $20.2 million available credit capacity[38]

Production and Operations - Second quarter net production was approximately 63,500 boepd[11] - Kosmos is targeting 27 mtpa FLNG nameplate capacity for GTA in the fourth quarter of 2025[9] - Jubilee's first producer from the 2025/26 drilling program came online in late July[9] - Winterfell-4 was successfully drilled and is expected to add approximately 1,000 boepd net rate when it comes online at the end of the third quarter of 2025[39] - Gross oil production from Ceiba & Okume averaged approximately 22,000 bopd in the second quarter[17] Financial Performance and Guidance - Kosmos expects fiscal year 2025 capital expenditures to be approximately $350 million, reduced from a previous estimate of $400 million[9,47] - Kosmos is targeting a $25 million overhead reduction by year-end 2025[10] - Kosmos has agreed to indicative terms for a Gulf of America term loan of up to $250 million to repay 2026 maturities[9,41] - Kosmos anticipates operating expenses per barrel of oil equivalent (Opex/boe) to decrease as production increases[9] - Kosmos expects 3Q 2025 net production to be 65,000 – 71,000 boe/day and FY 2025 net production to be 65,000 – 70,000 boe/day[50] Hedging and Risk Management - Kosmos has hedged 5 million barrels of remaining oil production for 2025 with a floor of approximately $62/barrel and a ceiling of approximately $77/barrel[47] - Kosmos has hedged 7 million barrels of oil production for 2026 with a floor of approximately $66/barrel and a ceiling of approximately $75/barrel, targeting approximately 50% of 2026 oil production to be hedged[47]